MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings
Por:
Pinana, JL, Valcarcel, D, Fernandez-Aviles, F, Martino, R, Rovira, M, Barba, P, Martinez, C, Brunet, S, Sureda, A, Carreras, E, Sierra, J
Publicada:
1 sep 2010
Resumen:
Mycophenolate mofetil (MMF) in combination with CsA seems to lead to earlier post transplant hematological recovery and less mucositis than MTX, with a similar incidence of GVHD. In this study we analyzed the post transplant outcomes of two cohorts of patients who underwent an HLA-identical sibling reduced intensity conditioning transplantation (allo-RIC) with GVHD prophylaxis consisting of CsA in combination with either MMF or a short course of MTX. We included 145 consecutive allo-RIC transplants performed between April 2000 and August 2007. The median follow-up for survivors was 41 months (4-105 months). The study group included 91 males. Median age was 55 years (range 18-71 years). Diagnoses included myeloid (n = 65) and lymphoid (n = 80) malignancies. GVHD prophylaxis consisted of CsA/MMF in 52 and CsA/MTX in 93 patients. The conditioning regimen was based on fludarabine in combination with BU (n = 59) or melphalan (n = 86). The occurrence of grade 2-4 mucositis was higher in the CsA/MTX group than in the CsA/MMF group (57 vs 23%, P = 0.001). The cumulative incidence of acute and chronic GVHD was similar, 48 vs 50% and 71 vs 68%, respectively (P>40.7). The 2-year relapse and OS were similar in the CsA/MTX and CsA/MMF groups (29 vs 21%, P = 0.3 and 52 vs 51%, P = 0.7, respectively). Our results support further prospective studies comparing the use of the CsA/MMF combination with CsA/MTX as GVHD prophylaxis in HLA-identical sibling donor allo-RIC recipients. Bone Marrow Transplantation (2010) 45, 1449-1456; doi:10.1038/bmt.2009.362; published online 8 February 2010
Filiaciones:
Pinana, JL:
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Div Clin Hematol, Barcelona 08041, Spain
Valcarcel, D:
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Div Clin Hematol, Barcelona 08041, Spain
Fernandez-Aviles, F:
Univ Barcelona, Dept Hematol, Hosp Clin, Barcelona, Spain
Martino, R:
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Div Clin Hematol, Barcelona 08041, Spain
Rovira, M:
Univ Barcelona, Dept Hematol, Hosp Clin, Barcelona, Spain
Barba, P:
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Div Clin Hematol, Barcelona 08041, Spain
Martinez, C:
Univ Barcelona, Dept Hematol, Hosp Clin, Barcelona, Spain
Brunet, S:
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Div Clin Hematol, Barcelona 08041, Spain
Sureda, A:
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Div Clin Hematol, Barcelona 08041, Spain
Carreras, E:
Univ Barcelona, Dept Hematol, Hosp Clin, Barcelona, Spain
Sierra, J:
Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Div Clin Hematol, Barcelona 08041, Spain
Bronze
|